Future growth expectations in sales/revenue/volumes?

Volumes increased substantially by more than 30% in Q2 FY24, though top-line growth was modest due to lower chemical prices. Expect stronger sales volumes and good margins in chemical distribution driven by support from principals and penetration into new markets. Export volumes in merchant export subdued due to US oil and gas sector recession, but expected to improve next financial year. Key products like ethanolamine, purified isophthalic acid, and acrylonitrile expected to improve in volume and revenues in upcoming quarters. Polyacrylamide liquid demand is expected to be robust, especially

Future growth expectations in earnings/operating earnings/profits/EPS?

Earnings growth driven by volume increase despite stable or falling chemical prices (p. 6, 11). EBITDA improved significantly due to better inventory management, higher export sales, and pricing support from principals (p. 4). Expect higher margins for current and upcoming quarters due to stable raw material prices, especially Acrylonitrile (p. 4). Expansion of export market for Acrylamide solids, expected to bring better price realizations and improved profitability (p. 8). New product developments like Polyacrylamide solids and specialty chemicals project expected to contribute by FY25 and b

IN US

Sale is live|00:00:00left today

Black Rose Industries LtdQ3 FY23Chemicals & Petrochemicals

Black Rose Industries Ltd Q3 FY23 Earnings Call Analysis

Q: Any current/future capex/capital investment/strategic investment?

R&D building expected to be in place by next year (FY25). Specialty chemical project in advanced stages; target for launch by FY25 at existing Jhagadia plant in collaboration with a Japanese principal. Discussions with US and European companies for toll manufacturing projects related to Acrylamide chemistries. Potential to expand Acrylamide liquid capacity by 60,000 MT at existing Jhagadia site when utilization consistently exceeds threshold. Capex for new capacity additions expected to be low but subject to statutory approvals. Continued focus on development and commercial launch of Polyacryl

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹90.2P/E: 21.8Market Cap: ₹491 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Volumes increased substantially by more than 30% in Q2 FY24, though top-line growth was modest due to lower chemical prices.
→Expect stronger sales volumes and good margins in chemical distribution driven by support from principals and penetration into new markets.
→Export volumes in merchant export subdued due to US oil and gas sector recession, but expected to improve next financial year.
→Key products like ethanolamine, purified isophthalic acid, and acrylonitrile expected to improve in volume and revenues in upcoming quarters.
→Polyacrylamide liquid demand is expected to be robust, especially with increased ceramic tile exports, supporting higher sales volumes and improved margins.
→Newer product developments (e.g., polycarboxylate dispersant, N-methylol acrylamide) anticipated to drive future revenue growth.
→Manufacturing revenue has potential to grow close to distribution revenues, moving towards a 50:50 mix as manufacturing scales up.
→Overall, focus on volume growth, export expansion, and new product launches underpin positive outlook.

Margin guidance

Category 3

→Earnings growth driven by volume increase despite stable or falling chemical prices (p. 6, 11).
→EBITDA improved significantly due to better inventory management, higher export sales, and pricing support from principals (p. 4).
→Expect higher margins for current and upcoming quarters due to stable raw material prices, especially Acrylonitrile (p. 4).
→Expansion of export market for Acrylamide solids, expected to bring better price realizations and improved profitability (p. 8).
→New product developments like Polyacrylamide solids and specialty chemicals project expected to contribute by FY25 and beyond (p. 12).
→N-Methylol Acrylamide sales expected to rise substantially with repeat orders from domestic and international customers (p. 5).
→Continuing volume growth in core products across domestic and international markets with improved profitability outlook (p. 2, 5).
→Management focused on boosting volume and profitability rather than capacity utilization alone; capacity expansions planned when needed (p. 7).

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or immediate new fundraising through debt or equity in the transcript.
→The company is currently debt-free with no long-term debt, as highlighted in the balance sheet discussion.
→They have substantial internal accruals available for funding future projects and working capital needs.
→Future capacity expansions and upcoming projects will likely be funded through internal accruals.
→No announcements or plans regarding raising funds through debt or equity were made during the Q&A or presentation.

Order book

The provided transcript from Black Rose Industries Limited's Q2 FY24 Earnings Webinar does not explicitly mention details about the current or expected order book or pending orders. However, relevant points indicating business outlook and demand include: - Strong volumes growth in both manufacturing and distribution segments, indicating healthy demand. - New customer additions in N-methylol Acrylamide (NMA) with initial commercial batches shipped in domestic and international markets; repeat orders expected. - Increasing export volumes for Acrylamide solids as an alternate to Chinese supply, indicating expanding order interest. - Robust demand expected for Polyacrylamide liquid in the festive season with growth plans. - Active development and upcoming launch of Polyacrylamide solid by Q3 FY25 expected to broaden product offering. - Discussions underway with US and European companies for toll manufacturing, suggesting potential future orders. No specific order book or pending order quantities were disclosed in the transcript.

Capex plans

Yes

- R&D building expected to be in place by next year (FY25). - Specialty chemical project in advanced stages; target for launch by FY25 at existing Jhagadia plant in collaboration with a Japanese principal. - Discussions with US and European companies for toll manufacturing projects related to Acrylamide chemistries. - Potential to expand Acrylamide liquid capacity by 60,000 MT at existing Jhagadia site when utilization consistently exceeds threshold. - Capex for new capacity additions expected to be low but subject to statutory approvals. - Continued focus on development and commercial launch of Polyacrylamide solids by Q3 of FY25. - Overall, strong internal accruals available for funding future projects and working capital needs; company remains zero long-term debt. These investments indicate ongoing strategic expansion and product development initiatives focused on specialty chemicals, capacity augmentation, and R&D infrastructure.

How does Black Rose Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Black Rose Industries Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Black Rose Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio